Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical Industries Ltd Sees FY 2013 Guidance Near Midpoint Of Prior Range-Conference Call


Thursday, 1 Aug 2013 08:00am EDT 

Teva Pharmaceutical Industries Ltd announced that for fiscal 2013, it anticipates ending the year near the midpoint of its original fiscal 2013 guidance of revenues between $19.5 billion to $20.5 billion and non-GAAP diluted earnings per share (EPS) of $4.85 to $5.15. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $20.1 billion and EPS of $5.01 for fiscal 2013. 

Company Quote

56.65
0.9 +1.61%
18 Dec 2014